4D Molecular Therapeutics, Inc. FDMT · SEC Filings

website

196

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic ...

Price12.48

Market Cap689.45 M

Float42.55 M

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

Financials

TYPE

HEADLINE

FILED AT

News

TYPE

HEADLINE

FILED AT

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Nov 6, 2025

424B5

Up to $250,000,000 Common Stock PROSPECTUS SUPPLEMENT Leerink Partners June 7, 2024

Jun 7, 2024

424B5

6,586,015 Shares of Common Stock

Feb 8, 2024

424B5

Common Stock

Feb 5, 2024

424B5

7,500,000 Shares

May 8, 2023

424B5

Risks Relating to Our Common Stock and This Offering

May 4, 2023

Registrations

TYPE

HEADLINE

FILED AT

S-3

May 2026 SHELF

May 7, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 18, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 8, 2025

POS AM

Form POS AM - Post-Effective amendments for registration statement

Feb 28, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 28, 2025

POSASR

Form POSASR - Post-effective Amendment to an automatic shelf registration statement

Feb 28, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 10, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 10, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

May 14, 2026

CORRESP

Form CORRESP - Correspondence

May 11, 2026

LETTER

Form UPLOAD - SEC-generated letter

May 8, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 25, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 16, 2023

CORRESP

Form CORRESP - Correspondence

Aug 11, 2023